Presentation of Strong Preclinical Dataset: On September 25, 2024, HOOKIPA presented the preclinical proof-of-concept dataset ...

An experimental vaccine could offer fresh hope to women diagnosed with an aggressive and hard-to-treat form of breast cancer, ...

Notes payable, plus accrued interest, totaled approximately $6.9 million. The current portion of the notes payable plus accrued interest totaled approximately $3.7 million. Included in the current ...

The company is paying China-based biotech LaNova Medicines $588 million for the same type of bispecific antibody drug that ...

Testing in advanced animal model planned in Q4 for smaller, 00-size BioJet device with largest capacity of any ingestible injectableCompany ...

MINNEAPOLIS--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for severe ischemic diseases, today announced that the first ...

Clene (NASDAQ: CLNN) reported its Q3 2024 financial results and provided updates on its CNM-Au8 programs. Key operational highlights included a recent FDA meeting to discuss the potential for ...

the potential therapeutic benefit of mavorixafor; the initiation, timing, progress, and results of our current and future preclinical studies and clinical trials, including the completed Phase 2 ...

In the world of nuclear medicine, health care professionals face the challenge of safeguarding themselves and their patients ...

“I am very encouraged by the progress of our gene therapy programs and the clinical and regulatory milestones achieved ... which are subject to risks and uncertainties. We may, in some cases, use ...

In the first half of 2025, Werewolf expects to provide an update on the WTX-124 clinical development program, including data ...

Recent Progress and Upcoming Late-Stage Pipeline Milestones The Company remains focused ... safety and immunogenicity. Propionic acidemia (PA) therapeutic: In an ongoing Phase 1/2 study designed to ...